J B Chemicals & Pharmaceuticals Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/6atft76ns01jiaof4kirei4z.pdf

Key Takeaways


Domestic Formulations: The Growth Engine

Chopra: "So we are looking organization from a theme of invest to grow, that is what is the intention."

CMO Business: Record Scale and Front-Loaded Demand

Chopra: "Probably the stocking part happens for us, calendar quarter is quarter 2. That is how things happen. And if the end customer demand continues to be there, then it should surprise all of us."

Azmarda: The Pre-LOE Investment Bet

Chopra: "We are keeping fingers crossed in terms of the overall strategy that we will put in place when the LOE sets in. And right now, what is stopped on the agenda is to how to at least have critical mass of patients who are getting diagnosed..."

Sanzyme Acquisition: Integration and Life-Cycle Management

Kataria: "We've invested it in a business called Sanzyme, which we brought EBITDA of about INR 50 crore a year. We feel that this INR 50 crore in the next 4 to 5 years can become INR 100 crore, right? That's our hypothesis and that was the whole logic of buying this business."

International Markets: Steady with Pockets of Traction


Margins and Profitability: A Volatile Bridge

Chopra: "So that is our guidance that we are putting across because you are living in a very volatile world. Please understand the overall geopolitical issues, the currencies, the receivables, all those things have to put in place."

Guidance & Commitments

CommitmentSpecificsTimeline
CMO full-year revenue shareClose to 13–14% of overall business (vs 10% last year)FY23
CMO Q2 revenueBetween Q4 (~INR 83 crore) and Q1 (INR 100 crore) figuresQ2 FY23
CMO full-year growthMid-teens growth, front-loaded in H1FY23
Sanzyme full-year revenueINR 140 crore to INR 150 croreFY23
Sanzyme new product launches1–2 life-cycle management products to offset H2 seasonality; new Sporlac variantsNext 2–3 months
Azmarda gross margin reliefSome relief in Q3; significant improvement when LOE expiresQ3/Q4 FY23
Azmarda post-LOE marginMinimum aspiration: slightly better than company average EBITDAPost-December 2022
Gross marginHope to sustain closer to 64% for the fiscalFY23
EBITDA margin24% to 26% band, with quarterly volatilityFY23
PAT trajectoryUpward trajectory as ESOP and treasury income normalize1–2 quarters
ROCEReturn to 30–35%Next 3–4 years
Prescription aspirationGrow from 4 crore to 6 crore"In coming time"
Paediatric brands performance updateMore information on tax rate and acquisition performanceQ3 FY23 onwards

Key Metrics

MetricQ1 FY23
Revenue₹785 cr, +30% YoY (20% organic, rest from acquisitions)
Domestic formulations revenue₹418 cr, all-time high; organic growth in mid-teens as compared to flat growth as reported in IPM
International business revenue₹366 cr, growth both YoY and QoQ
Gross marginClose to 63%, vs 64% in Q1 FY22; excluding Azmarda, gross margins were relatively flat
Operating EBITDA₹190 cr, +16% YoY; includes non-cash ESOP charge of ₹17 cr
Operating EBITDA margin24% plus, in line with 24%–26% guidance for FY23
PAT₹105 cr, -12% YoY, due to higher treasury income in base quarter, non-cash ESOP cost, depreciation of acquired brands, and finance costs
Employee expenses growth (ex-ESOP)+19% YoY, on account of annual increments and integration of acquired workforce
Net debt₹325 cr, largely to fund Azmarda acquisition; cash and investments over ₹180 cr
Domestic prescription base4.09 cr, +57% YoY (like-for-like per IQVIA)
IPM prescription rankingNumber 15, as per IQVIA
CMO segment revenue₹100 cr, ever highest; Q4 FY22 was ~₹83 cr
Sanzyme portfolio monthly run rate₹12–13 cr, growing mid to high teens; full-year revenue traction expected ₹140–150 cr
Azmarda monthly run rate₹7–8 cr, currently negative at EBITDA level
South Africa growthUpwards of 25% YoY, with public-private mix roughly 50-50
Field force size2,500 people, up from 2,000 organically, with 300 from Sanzyme and 200 from Azmarda